Table 3.
Relationship of tumor immune microenvironment and clinicopathological factors
| Variable | Type I | Type II | Type III | Type IV | P-value |
|---|---|---|---|---|---|
| Number | 30 | 71 | 29 | 40 | |
| Age | 0.645 | ||||
| ≥70 | 11 | 33 | 14 | 15 | |
| <70 | 19 | 38 | 15 | 25 | |
| Sex | 0.001 | ||||
| Male | 23 | 21 | 19 | 18 | |
| Female | 7 | 50 | 10 | 22 | |
| Smoking history | <0.001 | ||||
| Smoker | 24 | 21 | 19 | 16 | |
| Never | 6 | 50 | 10 | 24 | |
| Clinical T category (TNM-7) | 0.924 | ||||
| T1 | 22 | 54 | 19 | 27 | |
| T2 | 8 | 17 | 10 | 13 | |
| Histological subtype | 0.027 | ||||
| Lepidic | 6 | 33 | 5 | 14 | |
| Acinar | 9 | 19 | 10 | 15 | |
| Papillary | 9 | 16 | 10 | 10 | |
| Solid | 6 | 3 | 4 | 1 | |
| Pathological Nodal status | 0.253 | ||||
| N0 | 24 | 59 | 20 | 35 | |
| N1+2 | 6 | 12 | 9 | 5 | |
| Pathological stage (TNM-7) | 0.016 | ||||
| IA | 12 | 37 | 8 | 17 | |
| IB | 11 | 20 | 9 | 16 | |
| IIA+IIB | 4 | 4 | 4 | 5 | |
| IIIA | 3 | 10 | 8 | 2 | |
| EGFR mutation status | 0.001 | ||||
| Positive | 4 | 27 | 4 | 8 | |
| Negative | 13 | 9 | 13 | 14 | |
| Unknown | 13 | 35 | 12 | 18 |
Note: Type I (PD-L1 positive with TILs driving), type II (PD-L1 negative with no TIL), type III (PD-L1 positive with no TIL), and type IV (PD-L1 negative with TILs driving).
Abbreviations: PD-L1, programmed cell death-1 ligand 1; TILs, tumor-infiltrating T lymphocytes; TNM, tumor, node, and metastasis.